Register Login

Anticoagulant Therapy

Dec 8 2025
george

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs […]
read more
Comments (1)
Anticoagulant Therapy
Nov 24 2025
george

11-8-25 AHA Presentation Records Successful Reduction of Anticoagulation in AFIB

Click here for the results of a “One month of clot prevention after a stent was as effective as a Year-long course for AFIB.” Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received […]
read more
Comments (0)
Anticoagulant Therapy
Nov 19 2025
george

Viewpoint: Anticoagulation for Climate Resilient Care

Go to your medical library to obtain Fan BE, Milla K, McAlister S, et al, Sustainable anticoagulation for climate resilient care. Lancet Haematol. 2025;12:e918-e925. doi: 10.1016/S2352-3026(25)00204-2.  PMID: 40972616. Abstract This Viewpoint issues a multidisciplinary call to embed sustainability into anticoagulation care, aligning clinical excellence with climate responsibility. Anticoagulation management-including drug manufacturing, laboratory diagnostics, therapeutic monitoring, […]
read more
Comments (0)
Anticoagulant Therapy
Nov 17 2025
george

FXIa Inhibitor Milvexian Fails Pivotal Test

Because FXI deficiency is associated with mild variable bleeding, researchers have been developing a direct anticoagulant specific to FXIa, intending to provide effective anticoagulation while reducing the bleeding risk that plagues other antithrombotics. Here is a FirstWord Pharma post in which Bristol-Myers Squibb and Johnson & Johnson report an interim finding in their Librexia ACS (acute […]
read more
Comments (0)
Anticoagulant Therapy
Nov 14 2025
george

Commentary: Laboratory Implications of Transitioning from DOACs to Heparin.

Click here for an 11-13-2025  open-access article, Arachchillage DJ, Vinayagam S, Parsons A, Karawitage N, Laffan M. Transitioning of patients from direct-acting oral anticoagulant to heparin: impact on laboratory testing. Semin Thromb Hemost. 2025. doi: 10.1055/a-2734-2293. PMID: 41232561. Abstract Direct oral anticoagulants (DOACs), including direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (apixaban, rivaroxaban, […]
read more
Comments (0)
Anticoagulant Therapy
Nov 14 2025
george

Coag Conversation About Alternative Methods to Monitor Anticoagulant Therapy Part 2: Anticoagulation for Antiphospholipid Syndrome

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click Anticoagulation […]
read more
Comments (0)
Anticoagulant Therapy
Load more

George Fritsma MS MLS

George Fritsma is a medical laboratory scientist, educator, and author. George  is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

read more

Cheat Sheets from George

Name

Questions or Comments?

Email George

Quick Question

Which is NOT an endogenous coag control protein?